One article reported that in a patient with lung adenocarcinoma, who developed HPD after treatment with a PD-L1 blocking antibody, duvalumab, the vast majority of infiltrating CD8+ T cells in the tumor microenvironment were expressing PD-L1 in large amounts [71]. The gene discussed is CD8A; the disease is neoplasm.